Publications
Specialty
Search
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/08/2024
Results of the HUDDLE study indicated that the prevalence of hypertension in the 498 screened participants was 83.8%, though only about half (46.5%) self-reported a history of hypertension.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/08/2024
A late-breaking clinical trial confirms routine use of Impella CP in patients who have had a heart attack with STEMI cardiogenic shock reduces 180-day mortality by 12.7%, compared to the control arm (45.8% vs. 58.5%, p=0.04).
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/08/2024
New data demonstrate the early addition of twice-yearly* Leqvio (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), including those with a history of an ASCVD-related event, who could not reach their goal on statin therapy alone.(1)
Rheumatology & Arthritis
04/08/2024
In this podcast, Drs England and Smith discuss the key recommendations and how to implement exercise, rehabilitation, diet, and additional interventions as part of an integrative management approach for people with rheumatoid arthritis.
Journal of Clinical Pathways
04/08/2024
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/07/2024
The KARDIA-2 study achieved its primary endpoint demonstrating clinically and statistically significant additive, placebo-adjusted reductions of up to 12.1 mmHg in 24-hour mean systolic blood pressure (SBP) measured by ambulatory blood pressure monitoring (ABPM) when zilebesiran was added to a thiazide-like diuretic, calcium channel blocker or angiotensin receptor blocker, measured independently at Month 3.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/07/2024
Withdrawing aspirin one month after percutaneous coronary intervention (PCI) in high-risk heart patients and keeping them on ticagrelor alone safely improves outcomes and reduces major bleeding by more than half when compared to patients taking aspirin and ticagrelor combined (also known as dual antiplatelet therapy or DAPT), which is the current standard of care.
Cath Lab Digest, Journal of Invasive Cardiology, Vascular Disease Management, CardioVascular
04/07/2024
The CERAB technique (covered endovascular reconstruction of the aortic bifurcation) in combination with the BeGraft aortic and two BeGraft peripheral stents provide a treatment option especially for high-risk patients for whom open surgery is unsuitable.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/07/2024
The one-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial in individuals with aortic stenosis (AS) with small aortic annuli (SAA) demonstrated noninferior clinical outcomes and superior valve performance as measured by bioprosthetic valve dysfunction performance for the Evolut™ TAVR platform compared to the SAPIEN™ platform.
Cath Lab Digest, Vascular Disease Management, Journal of Invasive Cardiology, CardioVascular
04/07/2024
Study author Dr. Ki Hong Lee of Chonnam National University Hospital, Gwangju, Republic of Korea said: “Patients with diabetes tend to put pressure on the metatarsal area of the foot, rather than the heel. This way of walking encourages ulcers, which can become infected and lead to amputation."
Oncology, Lymphoma, Leukemia & Myeloma Network
04/06/2024
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, John Allan, MD, shares expert insight on the impact targeted agents have in the treatment of CLL, focusing particularly on frontline therapy.
Oncology, Lymphoma, Leukemia & Myeloma Network
04/06/2024
During the Great Debates & Updates in Hematologic Malignancies meeting, Samuel Yamshon, MD, examines the efficacy of using CAR T-cell therapy to treat elderly patients with relapsed/refractory diffuse large B-cell lymphoma.
Oncology, Lymphoma, Leukemia & Myeloma Network, First Report Managed Care
04/06/2024
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting in New York, Peter Martin, MD, argued in favor of alternative treatment regimens over CAR T-cell therapy for treating follicular lymphoma.
Advances in Inflammatory Bowel Disease Network
04/06/2024
Dr Axelrad discusses his presentation at the AIBD regional meeting on the value and positioning of sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease.
Advances in Inflammatory Bowel Disease Network
04/06/2024
Millie Long, MD, reviewed the results of clinical trials and real-world experience into the treatment of inflammatory bowel disease with Janus kinase inhibitors at the AIBD Regional Meeting April 6 in Boston.
Journal of Clinical Pathways
04/06/2024
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Lymphoma, Leukemia & Myeloma Network
04/06/2024
Jia Ruan, MD, PhD, shares various active evaluations and topics of interest within the MCL treatment landscape, including the comparison between novel combinations versus traditional chemoimmunotherapy.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/06/2024
This is the first study to analyze the impact of inter-atrial shunts in patients with both reduced and preserved LVEF and the first to show different outcomes in these two groups. “Although further studies are required to confirm our observations, the present results strongly suggests that heart failure patients with reduced LVEF may benefit from these devices,” says Gregg W. Stone, MD, one of the Principal Investigators of RELIEVE-HF, who presented the trial results.
Lymphoma, Leukemia & Myeloma Network
04/06/2024
At the 2024 Great Debates & Updates Meeting in Hematological Malignancies in New York, John Allan, MD, discusses if there is a role for chemo-immunotherapy in the CLL treatment landscape.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/06/2024
The research assessed the prevalence of cardiovascular disease (CVD) risk factors and the use of preventative CVD medications over the past 20+ years in a large Midwest STEMI system. Data included in the study were from 2003 through 2022 in 7,854 first-time STEMI patients.
Current Issue
September 2024
Volume
Issue
Enter Your E-mail
EMSWorld Newsletter
